0.542
-0.02 (-3.71%)
| Previous Close | 0.563 |
| Open | 0.545 |
| Volume | 761,455 |
| Avg. Volume (3M) | 1,748,679 |
| Market Cap | 41,692,588 |
| Price / Sales | 252.22 |
| Price / Book | 4.42 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2024 - 15 Nov 2024 |
| Operating Margin (TTM) | -51,661.19% |
| Diluted EPS (TTM) | -0.690 |
| Total Debt/Equity (MRQ) | 915.08% |
| Current Ratio (MRQ) | 0.460 |
| Operating Cash Flow (TTM) | -30.23 M |
| Levered Free Cash Flow (TTM) | -18.18 M |
| Return on Assets (TTM) | -92.94% |
| Return on Equity (TTM) | -914.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Eyenovia, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.00% |
| % Held by Institutions | 13.73% |
| 52 Weeks Range | ||
| Median | 2.00 (268.94%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 18 Nov 2024 | 2.00 (268.94%) | Hold | 0.111 |
| 13 Nov 2024 | 12.00 (2,113.61%) | Buy | 0.408 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Dec 2024 | Announcement | Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering |
| 25 Nov 2024 | Announcement | Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering |
| 22 Nov 2024 | Announcement | Eyenovia Provides Update on Restructuring Efforts |
| 15 Nov 2024 | Announcement | Eyenovia Provides Update on Phase 3 CHAPERONE Study |
| 12 Nov 2024 | Announcement | Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
| 07 Nov 2024 | Announcement | Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th |
| 23 Oct 2024 | Announcement | Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet® |
| 16 Oct 2024 | Announcement | Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |